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in the midline of the body, particularly in the retroperi-
toneum and the mediastinum.
GCT has attracted major interest from medical on-
cologists because of its uniquely good response to com-
bination chemotherapy. During the last three decades, 
GCT has become the most curable type of solid tumor 
even at an advanced stage. Seventy to 80％ of patients 
with metastatic GCTs can be cured with cisplatin-
based combination chemotherapy with or without sur-
gical excision of post-chemotherapy residual masses4）. 
The remaining 20％ to 30％ of metastatic GCTs be-
come candidates for salvage chemotherapy, either be-
cause of incomplete response to primary chemothera-
py or because of relapse after complete remission 
（CR）4,5）. Various strategies have been utilized as sec-
????????????
Germ cell tumor （GCT） account for only 1％ of all 
cancers in men1）, but are the most common solid tu-
mor in males between 15 and 35 years of age, a popu-
lation in whom all cancers are rare 2）. Approximately 
95％ of malignant tumors arising in the testis are 
GCTs, with other testicular neoplasms occurring more 
rarely. Approximately 5-7％ of GCT arises in extrago-
nadal sites3）. Extragonadal GCTs most commonly arise 
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???????
About one half of all advanced germ cell tumor （GCT） patients with poor prognosis defined by the Inter-
national Germ Cell Cancer Collaborative Group （IGCCCG） die of cancer. We evaluated salvage high-dose 
chemotherapy （HDCT） with peripheral blood stem cell transplantation （PBSCT） for patients with poor 
prognosis advanced GCT in Dokkyo Medical University. Three patients with poor prognosis advanced GCT 
were treated with HDCT as salvage chemotherapy. Two patients had primary testicular GCT and one pa-
tient had primary mediastinal GCT. Treatment responses were pathological complete remission （CR） in one, 
surgical CR in one and partial remission （PR） in one. Effectiveness and side effects of HDCT with PBSCT 
for poor prognosis cases with advanced GCT were shown in this study. However, further accumulation of 
these studies is needed.
???? ????： Advanced germ cell tumor, Poor prognosis, High dose chemotherapy, Peripheral blood stem 
cell transplantation
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with poor risk advanced GCT （poor prognosis of 
IGCCCG or advanced extent of Indiana University 
stage）11）. In this report, we evaluated our HDCT with 
PBSCT for patients with poor prognosis advanced 
GCT.
Patients
We treated three patients with poor prognosis ad-
vanced GCT between April 1995 and January 2006 . 
All three patients were treated with HDCT as salvage 
chemotherapy. Patient characteristics and patient sta-
tus before HDCT are summarized in Tables 1 and 2 . 
All patients were male with an average age of 28 .3 
years （range 21-40）. Two patients had primary testic-
ond-line chemotherapy after failure to cure with pri-
mary cisplatin-based combination chemotherapy. This 
includes standard-dose regimens with cisplatin plus if-
osfamide plus either etoposide6） or paclitaxel 7） or 
HDCT with peripheral blood stem cell transplantation 
（PBSCT）8）. There are no randomized studies proving 
the superiority of one approach compared with anoth-
er. However, for patients who are refractory to stan-
dard dose cisplatin-based combination chemotherapy, 
HDCT has been the logical approach offering a distinct 
possibility for long-term survival and cure9）.
Prognostic factor studies in advanced GCT have led 
to the definition of risk groups suitable for different 
treatment strategies；most recently, the International 
Germ Cell Cancer Collaborative Group （IGCCCG） has 
produced a widely accepted classification system for 
advanced GCTs10）. The patient population is divided 
into 3 groups defined as good, intermediate and poor 
prognosis groups respectively. These groups comprise 
60％, 26％ and 14％ of advanced GCT patients, with 
corresponding cure rates of approximately 90％, 80％ 
and 50％10）. Since about one half of all patients with 
poor prognosis advanced GCT die of cancer, current 
clinical investigations seeking to improve survival in 
these patients have focused on developing more effec-
tive chemotherapy treatments. One of the important 
strategies for poor prognosis advanced GCT patients 
has been based on the use of more intensive chemo-
therapy. It is very important to report the evaluation 
of the treatment experience of advanced GCT with 
poor prognosis, in order to share useful knowledge of 
these few and valuable cases. Hasumi et al. reported 
the original article of HDCT with PBSCT for 5 patients 
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???????　Patient’s characteristics
Age Pathology Tumor marker Metastases
a-FP HCG b-HCG LDH
（ng/ml） （IU/l） （ng/ml）（mU/ml）
（1） 40 IT, MT, E, Y 10400 10900 210 1928 RPLN, Lung
（2） 24 S, E, Y 33100 740 7.1 2904 RPLN, Lung
（3） 21 IT 88800 （not evaluated） 507 LN
（mediastinal primary）
IT；Immature Teratoma, MT；Mature teratoma, E；Embryonal carcinoma, Y；Yolk 
sac tumor, S；Seminoma, RPLN；Retro-peritoneal lymph node, LN；lymph node
a-FP；alpha fetoprotein, HCG；human chorionic gonadotropin,
b-HCG；beta human chorionic gonadotropin, LDH；lactate dehydrogenase
???????　Status before HDCT
Pre-HDCT
Prior chemotherapy a-FP b-HCG LDH
（ng/ml）（ng/ml）（mU/ml）
（1）VIP （2 cycles） 71 0.5 474
（2）BEP （2 cycles） 347 0.1 396
（3）EP （3 cycles）, VIP （1 cycle） 44400 2.5 371
VIP；
Etoposide 100 mg/m2/day （day 1〜day 5）
Ifosfamide 1.2 g/m2/day （day 1〜day 5）
Cisplatin 20 mg/m2/day （day 1〜day 5）
BEP；
Bleomycin 30 mg/day （day 1, day 8, day 15）
Etoposide 100 mg/m2/day （day 1〜day 5）
Cisplatin 20 mg/m2/day （day 1〜day 5）
EP；
Etoposide 100 mg/m2/day （day 1〜day 5）
Cisplatin 20 mg/m2/day （day 1〜day 5）
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and normal tumor markers were considered PRm−；
PRm＋required a decline of tumor markers without 
normalization post-HDCT. No change （NC） was de-
fined as no objective decrease in the tumor measure-
ments qualifying as PR and no objective increase quali-
fying as progressive disease （PD）；and PD was 
defined as greater than 25％ increase in the product of 
the longest perpendicular diameters of any measurable 
lesion or the appearance of new lesions or an increase 
in serum markers. Patients with normalization of tu-
mor markers and complete resection of all residual 
masses were considered to have “no evidence of dis-
ease” （NED）. Toxicity was evaluated according to the 
National Cancer Institute-Common Terminology Crite-
ria for Adverse Event version 3.0 （NCI-CTCAE v3.0） 
classification.
???????
Therapeutic results
Therapeutic results and current status for each pa-
tient are summarized in Tables 3 and 4. Two patients 
are currently alive. One patient died of progressive 
disease after completion of therapy. Treatment re-
sponses were one pCR, one sCR and one PRm＋.
Subsequent therapy and survival
Case 1 underwent retro-peritoneal lymph node dis-
section （RPLND） and thoracotomy after HDCT, and 
histological examination proved that the masses were 
mature teratoma and embryonal carcinoma （sCR）. Ad-
juvant chemotherapy （paclitaxel, gemcitabine and 
nedaplatin；TGP） was performed, and his status has 
remained NED for 9 4 months. Case 2 underwent 
RPLND after HDCT, and histological examination 
proved the mass to be necrotic tissue （pCR）. Thereaf-
ter, he developed adrenal metastasis and lymph node 
of Virchow metastasis, and TGP chemotherapy was 
performed. Adrenalectomy and lymph node dissection 
were performed because all abnormally elevated se-
rum tumor marker values returned to normal. Histo-
logical examination proved the mass of the adrenal 
gland to be yolk sac tumor and that of the lymph node 
of Virchow to be seminoma. Adjuvant chemotherapy 
（TGP） was performed, and he has remained NED for 
52 months. One patient could not continue HDCT after 
two cycles of HDCT because of poor tolerance due to 
ular GCTs and one patient had primary mediastinal 
GCT. Both patients with testicular GCT underwent 
radical orchiectomy. One patient with mediastinal pri-
mary GCT underwent partial resection of the mediasti-
nal tumor. Histological types of GCT were non-semino-
mas in two and mixed type of seminoma and non-
seminoma in one. Follow–up periods for these patients 
were 105 months, 148 months and 11 months, respec-
tively.
Treatment
Treatment consisted of standard dose cisplatin-
based combination chemotherapy plus granulocyte-
colony stimulating factor （G-CSF） followed by periph-
era l  b lood s tem ce l l  （ PBSC） co l lec t ion and 
subsequently HDCT with PBSCT. It was planned to 
separate sufficient numbers of PBSC in order to sup-
port each course of HDCT with approximately 2×106 
CD34＋ cells/kg body weight. HDCT consisted of 
etoposide 400 mg/m2, ifosfamide 2.0 g/m2 and carbopla-
tin 300 mg/m2 given intravenously on days −6, −5, 
−4 and −3 during each cycle of therapy. The day of 
PBSCT was designated as day 0；the days before are 
indicated as minus and the days following are indicat-
ed as plus. All patients were scheduled to receive au-
tologous PBSC support with＞2×106 CD34＋ cells/kg 
body weight retransfused on day 0 of each HDCT cy-
cle. All patients received G-CSF, 5 mg/kg/day start-
ing on day 0 and continuing until blood cell count re-
covery. If all abnormally elevated serum tumor marker 
values returned to normal, residual tumor was resect-
ed when it seemed to be including viable tumor cells.
Evaluation of response
Patients with complete disappearance of all tumor 
lesions including marker normalization with chemo-
therapy alone were classified as achieving complete re-
mission （CR）. If patients became free of disease only 
after additional resection of necrosis or mature terato-
ma, they were considered to have achieved ’pathologi-
cal complete remission’ （pCR） and if viable undifferen-
tiated tumor elements could be demonstrated, they 
were considered to have achieved ’surgical complete 
remission’ （sCR）. Partial remission （PR） was defined 
as a＞50％ reduction in the sum of the products of the 
longest perpendicular diameters of measurable lesions, 
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Remarkable progress has been made in the medical 
treatment of metastatic GCTs, achieving a substantial 
increase in cure rates from approximately 25％ in the 
mid-1970s to nearly 80％ today5）. The successful man-
agement of advanced GCTs with cisplatin-based com-
bination chemotherapy with or without surgical exci-
sion of post-chemotherapy residual masses stands as a 
milestone in medical oncology. Improved treatment 
outcome for metastatic GCTs was observed in a ran-
domized trial of a combination with bleomycin, etopo-
side and cisplatin （BEP） as standard treatment2）. For 
advanced GCT, drug resistance is the major cause of 
treatment failure. The development of drug resistance 
is dose-related and one important component of cura-
severe toxicities despite a response to HDCT. The pa-
tient underwent standard dose VIP chemotherapy af-
ter two cycles of HDCT, but died of progressive dis-
ease 5 months after HDCT.
Treatment side effects
Toxicities are summarized in Table 5. As expected 
all patients experienced severe hematological toxicities, 
but all showed complete hematological recovery after 
stem cell re-infusion. There were no deaths, and none 
of the patient required hemodialysis or developed 
chronic renal insufficiency. Apart from hematological 
toxicity, side effects consisted mainly of gastrointesti-
nal events and infectious complications. Gastrointesti-
nal side effects were mostly manageable by supportive 
measures such as antiemetic therapy.
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???????　Current status of patients
Prognosis Additional
treatment
（1） Surgical CR TGP （3 cycles）
（NED：more than 94 months）
（2） Pathological CR TGP （7 cycles）
→ Relapse Adrenalectomy → Y
（Adrenal gland and LN of Virchow） LND → S
（NED：more than 52 months）
（3） PR m（＋） → PD （Dead） VIP （3 cycles）
CR；Complete remission, NED；No evidence of disease, 
LND；lymph node dissection
TGP；
Paclitaxel 160 mg/m2/day （day 1, day 8）
Gemcitabine 1000 mg/m2/day （day 1, day 8）
Nedaplatin 100 mg/m2/day （day 2）
???????　Therapeutic results
HDCT
Post HDCT Radiological
response
Surgery for
residual tumor
Pathology
a-FP b-HCG LDH
（ng/ml）（ng/ml） （mU/ml）
（1） 2 cycles 5 0.1 288 PR RPLND → MT
Thoracotomy → E
（2） 2 cycles 5 0.1 207 PR RPLND → viable cell （−）
（3） 2 cycles 332 1.8 132 PR （−）
HDCT；High dose chemotherapy
Etoposide：400 mg/m2/day （day −6〜day −3）
Ifosfamide 2.0 g/m2/day （day −6〜day −3）
Carboplatin 300 mg/m2/day （day −6〜day −3）
PR；Partial remission, RPLND；Retro-peritoneal lymph node dissection
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formed. Case 3 received HDCT as third line chemo-
therapy, because the patient was referred to our 
hospital after first line chemotherapy without collect-
ing PBSC. Although the half-lives of serum tumor 
makers were prolonged in this patient, he received 
standard dose cisplatin-based combination chemother-
apy as second-line chemotherapy in order to collect 
PBSC.
Einhorn et al. reported that advanced GCT is poten-
tially curable by HDCT, even when this regimen is 
used as second-line, third-line or later therapy 13）. A 
randomized trial of three cycles of standard dose cispl-
atin-based combination chemotherapy plus one cycle 
of HDCT compared with four cycles of conventional 
dose cisplatin-based combination chemotherapy did 
not show any survival benefit14）. It may be that multi-
ple cycles of HDCT are necessary to achieve a favor-
able outcome, and therefore, the single cycle of HDCT 
given in that trial may not have significantly affected 
the outcome. Motzer et al. pointed out that dose-inten-
sive therapy for patients with a poor-risk advanced 
GCT who have had minimal prior therapy is preferred 
over treatment of heavily pretreated patients because 
chemotherapy-related myelotoxicity is cumulative 15）. 
Non-randomized studies of first line sequential HDCT 
（one cycle of standard dose cisplatin-based combina-
tion chemotherapy followed by three to four sequential 
cycles of HDCT） for patients with a poor-risk ad-
vanced GCT demonstrated preliminary results that 
compared favorably to historical data16,17）.
Recently, treatment programs have incorporated 
primary HDCT in the treatment strategy for previous-
ly untreated patients with a poor-risk advanced GCT. 
Droz et al. did not support the use of primary HDCT 
tive experimental drug schedules is the use of a com-
bination of cytotoxic agents at their maximum tolerat-
ed doses （MTDs）. It may be clear that resistance to 
chemotherapy must be overcome by the introduction 
of non-cross resistant drugs and drug dose increment. 
Although less toxic treatment is being investigated for 
patients with good prognosis advanced GCT, one of 
the important strategies for patients with poor progno-
sis advanced GCT has been the use of more intensive 
chemotherapy.
There is no consensus as to whether HDCT should 
be given to any defined subset of advanced GCT pa-
tients. At Memorial Sloan-Kettering Cancer Center12）, 
all patients with advanced GCT were treated with two 
cycles of standard dose cisplatin-based combination 
chemotherapy. Serum tumor markers were deter-
mined weekly （days 6 , 14 , 21） during each cycle of 
chemotherapy. Before administration of the third cycle 
of chemotherapy, half-lives of serum tumor markers 
were calculated starting from the day 6 value and 
used to direct further therapy. If the serum tumor 
markers were rising or the half-life was prolonged 
（unsatisfactory marker decline）, therapy was changed 
to HDCT （two cycles of HDCT） with PBSCT. If the 
serum tumor markers showed a decline in their re-
spective half-lives （satisfactory marker decline）, the 
patient was considered an early responder and re-
ceived additional cycles of standard dose cisplatin-
based combination chemotherapy. In the present 
study, two patients received HDCT as second line che-
motherapy. In both patients, the half-lives of serum tu-
mor markers were prolonged before administration of 
the third cycle of chemotherapy. Therefore, the treat-
ment strategy was changed, and HDCT was per-
??（1） （2011） 21
???????　Side effects
NCI-CTCAE v3.0 grade
0 1 2 3 4
Leukopenia 3 cases
Thrombocytopenia 1 case 2 cases
Fever 1 case 2 cases
Nausea 3 cases
Anorexia 1 case 2 cases
Renal dysfunction 3 cases
NCI-CTCAE v3.0；National Cancer Institute-Common Terminology 
Criteria for Adverse Event version 3.0
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and 99 months. Furthermore, Einhorn et al. suggested 
that long-term disease-free survival is possible with 
paclitaxel plus gemcitabine in the patient population 
that progressed after HDCT, and had not previously 
received paclitaxel or gemcitabine22）. In this phase II 
study, they reported that the overall response rate and 
CR rate were 31％ and 12.5％ in thirty-two patients. 
In our study, 2 patients were treated with paclitaxel, 
gemcitabine and nedaplatine （TGP） after HDCT, and 
sCR was achieved in one and NC in one and these two 
have remained disease-free survivors for more than 
52 and 94 months, respectively. Ongoing research in 
this area may not only improve the treatment of pa-
tients with refractory disease but also facilitate further 
insight into the mechanisms of drug resistance. It is 
hoped that increased knowledge of the molecular 
mechanisms underlying GCT will lead to the develop-
ment of further new therapeutic options.
Conclusion
In the present study, HDCT with PBSCT can be 
used in poor prognosis GCTs with acceptable toxicity, 
and represents an effective salvage treatment. Howev-
er, data from more patients should be accumulated in 
order to describe final conclusions regarding the effec-
tiveness of HDCT with PBSCT for poor prognosis ad-
vanced GCTs.
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